WHO ICTRP trial
A twenty-four week, open-label, non-comparative, multicenter study to assess the…
EUCTR2008-002797-36-HU · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2008-002797-36-HU |
|---|---|
| Public title | A twenty-four week, open-label, non-comparative, multicenter study to assess the efficacy and tolerability of an aliskiren-based treatment algorithm in patients with mild to moderate hypertension. |
| Scientific title | A twenty-four week, open-label, non-comparative, multicenter study to assess the efficacy and tolerability of an aliskiren-based treatment algorithm in patients with mild to moderate hypertension. |
| Primary sponsor | Novartis Pharma Services AG |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Hungary;France |
| Conditions | hypertension MedDRA version: 9.1 Level: LLT Classification code 10015488 Term: Essential hypertension |
| Interventions | Trade Name: Rasilez Pharmaceutical Form: Film-coated tablet INN or Proposed INN: aliskiren Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Film-coated tablet Route… |
| Registration date | Oct 7, 2008 |
| Target size | 230 |
| Secondary IDs | CSPP100A2360 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: